PMID- 33463100
OWN - NLM
STAT- MEDLINE
DCOM- 20210916
LR  - 20210916
IS  - 1735-5249 (Electronic)
IS  - 1735-1502 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Aug 25
TI  - Intravenous Immunoglobulin Therapy in Myocarditis.
PG  - 323-336
LID - 10.18502/ijaai.v19i4.4109 [doi]
AB  - Myocarditis is an inflammatory disease of the myocardium with lymphocyte 
      infiltration and myocyte necrosis leading to a wide range of clinical 
      presentations including heart failure, arrhythmia, and cardiogenic shock. 
      Infectious and noninfectious agents may trigger the disease. The fact that 
      immunosuppressive drugs are useful in several kinds of autoimmune myocarditis is 
      proof of the autoimmune mechanisms involved in the development of myocarditis. 
      Pathogenic mechanisms in myocardial inflammation are including inflammasome 
      activation followed by myocyte destruction, myocarditis, and pericarditis. 
      Intravenous immunoglobulin (IVIG) is a serum product made up of immunoglobulins, 
      widely used in a variety of diseases. This product is effective in several 
      immune-mediated pathologies. As well as the determined usage of IVIG in Kawasaki 
      disease, IVIG may be useful in several kinds of heart failure including fulminant 
      myocarditis, acute inflammatory cardiomyopathy, Giant Cell Myocarditis, and 
      peripartum cardiomyopathy. Generally, IVIG is used in two different doses of low 
      dose (200 to 400 mg/kg) and high dose (2 g/kg) regimen. The exact therapeutic 
      effects of IVIG are not clear, however over the last decades, our knowledge about 
      its mechanism of function has greatly enhanced. IVIG administration should be 
      based on the accepted protocols of its transfusion. In this review article, we 
      try to provide an overview of the different kinds of myocarditis, pathologic 
      mechanisms and their common treatments and evaluation of the administration of 
      IVIG in these diseases. Furthermore, we will review current protocols using IVIG 
      in each disease individually.
FAU - Mansourabadi, Amir Hossein
AU  - Mansourabadi AH
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran. a.mansourabadi.67@gmail.com.
FAU - Gol Mohammad Pour Afrakoti, Ladan
AU  - Gol Mohammad Pour Afrakoti L
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran. ladan.gmp.93@gmail.com.
FAU - Shahi, Abbas
AU  - Shahi A
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran AND Students Scientific Research Center, Tehran University 
      of Medical Sciences, Tehran, Iran. abbas.shahi2012@yahoo.com.
FAU - Shabanian, Reza
AU  - Shabanian R
AD  - 3 Department of Pediatric Cardiology, Children's Medical Center Hospital, Tehran 
      University of Medical Sciences, Tehran, Iran. rzshabanian@sina.tums.ac.ir.
FAU - Amirzargar, Aliakbar
AU  - Amirzargar A
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran. Amiralizar@tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Disease Susceptibility/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*therapeutic use
MH  - Immunosuppressive Agents/administration & dosage/*therapeutic use
MH  - Myocarditis/diagnosis/*drug therapy/etiology/metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - High dose intravenous immunoglobulin
OT  - Inflammation
OT  - Intravenous immunoglobulin
OT  - Low dose intravenous immunoglobulin
OT  - Myocarditis
EDAT- 2021/01/20 06:00
MHDA- 2021/09/18 06:00
CRDT- 2021/01/19 07:08
PHST- 2019/09/14 00:00 [received]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2021/01/19 07:08 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - 10.18502/ijaai.v19i4.4109 [doi]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2020 Aug 25;19(4):323-336. doi: 
      10.18502/ijaai.v19i4.4109.